Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Meeting tentatively scheduled for April 22-23, according to Jan. 3 Federal Register notice listing FDA advisory committee dates in 2002. NDAC, which last met in May 2001 to consider switching second-generation antihistamines, may be asked to revisit OTC suitability of cholesterol-lowering statin drugs; in July 2000, committee voted against switching Pravachol (Bristol-Myers Squibb), Mevacor (Merck). FDA's TSE committee is slated to meet Jan. 16-17, June 26-27, Oct. 17-18; Food Advisory Committee is scheduled to meet June 4-5, Sept. 24-25...

Related Content

Acetaminophen Toxicity Headed To NDAC, New FDA Drug Safety Group





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts